|
CRSP | Crispr Therapeutics Ag |
|
|
CRSP | Crispr Therapeutics Ag |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 1.43 |
| Leverage | 14.39% |
| Market Cap | $ 4.0B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -384.7m |
| Margin | -295.68% |
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.